Welcome to our dedicated page for Cspc Pharmaceuti news (Ticker: CSPCY), a resource for investors and traders seeking the latest updates and insights on Cspc Pharmaceuti stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cspc Pharmaceuti's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cspc Pharmaceuti's position in the market.
Elevation Oncology has announced the selection of an abstract for SYSA1801 (EO-3021) Phase 1 clinical data for presentation at the ASCO 2023 Annual Meeting in Chicago, from June 2-6, 2023. The ongoing Phase 1 study is focused on evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors, conducted in partnership with CSPC Pharmaceutical Group in China. Elevation plans to advance its clinical trial for EO-3021 in the U.S. in the second half of 2023. EO-3021 targets Claudin 18.2, a significant unmet need in oncology, particularly for gastric and pancreatic cancers, with no existing approved therapies. The U.S. FDA has cleared an Investigational New Drug application for EO-3021.
Corbus Pharmaceuticals Holdings has entered an exclusive licensing agreement with CSPC Pharmaceutical Group for the development of CRB-701, an antibody drug conjugate targeting Nectin-4. This drug is being developed for various cancers, including urothelial, lung, breast, and prostate. An upfront payment of $7.5 million will be made to CSPC, with potential milestone payments totaling $685 million. The agreement also includes a 1-for-30 reverse stock split effective February 14, 2023, aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00. Corbus aims to initiate US clinical trials in 2024.
Elevation Oncology has secured exclusive global rights (excluding Greater China) to develop EO-3021 (SYSA1801), a clinical-stage ADC targeting Claudin18.2, expected to initiate a U.S. Phase 1 trial in 2023. This licensing agreement with CSPC Megalith includes a $27 million upfront payment and up to $1.148 billion in potential milestone payments. The addition of EO-3021 enhances Elevation's precision oncology pipeline, focusing on genomically defined solid tumors. The agreement marks a significant step in Elevation's growth strategy and potential market expansion.
FAQ
What is the current stock price of Cspc Pharmaceuti (CSPCY)?
What is the market cap of Cspc Pharmaceuti (CSPCY)?
